← 返回

下一代免疫治疗:增强多克隆 T 细胞的干性以提高抗肿瘤活性

英文原题:Next generation immunotherapy: enhancing stemness of polyclonal T cells to improve anti-tumor activity.

查看英文原题

Next generation immunotherapy: enhancing stemness of polyclonal T cells to improve anti-tumor activity.

PubMed 2021/10/26(内容时间) Curr Opin Immunol Q1 · IF 5.6(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

T细胞作为细胞疗法用于治疗晚期癌症已为许多患者带来临床获益,并推动了癌症研究领域的发展。然而,目前的细胞疗法对大多数患者并非治愈性,尤其是在实体瘤患者中,其未来能否广泛而有效地应用仍有待观察。近期研究已开始阐明调控癌症患者细胞疗法疗效的关键因素,包括T细胞干性以及有效靶向肿瘤抗原和克服肿瘤异质性的能力。在本综述中,我们讨论了临床有效抗癌T细胞疗法的关键特性,以及改善T细胞特征以增强实体瘤临床疗效的策略。

展开英文摘要原文

The administration of T cells as cellular therapy against advanced cancers has brought clinical benefit to many patients and has progressed the field of cancer research.

However, current cell therapy treatments are not curative in most patients, particularly in those with solid tumors, and it remains to be seen how broadly and efficaciously they may be applied going forward.

Recent research has begun to elucidate key factors that regulate the efficacy of cell therapy in cancer patients, including T cell stemness and the ability to effectively target tumor antigens and overcome tumor heterogeneity. In this review, we discuss key properties of clinically effective anti-cancer T cell therapies along with strategies to improve T cell characteristics to augment clinical efficacy in solid tumors.

论文信息

作者
Kishton RJ、Vodnala SK、Vizcardo R、Restifo NP
第一作者单位
Lyell Immunopharma Inc., South San Francisco, CA, USA. Electronic address: rkishton@lyell.com.United States
通讯作者单位
Lyell Immunopharma Inc., South San Francisco, CA, USA. Electronic address: nrestifo@lyell.com.United States
文献类型
综述
期刊
Current opinion in immunology2022 Feb
原文标识
PubMed 34710751 · DOI 10.1016/j.coi.2021.10.001